Prognostic impact of cardiohepatic syndrome in patients with ST-segment elevation myocardial infarction - Supplementary Figure

Background: Cardiohepatic syndrome (CHS) indicates a bidirectional interaction between the heart and

liver. This study was designed to evaluate the impact of CHS on in-hospital and long-term mortality in

patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous

coronary intervention. Materials & methods: 1541 consecutive STEMI patients were examined. CHS was

defined as the elevation of at least two of three cholestatic liver enzymes: total bilirubin, alkaline

phosphatase and gamma-glutamyl transferase. Results: CHS was present in 144 (9.34%) patients.

Multivariate analyses revealed CHS as an independent predictor of in-hospital (odds ratio: 2.48; 95% CI:

1.42–4.34; p = 0.001) and long-term mortality (hazard ratio: 2.4; 95% CI: 1.79–3.22; p < 0.001). Conclusion:

The presence of CHS is a predictor of poor prognosis in patients with STEMI and should be evaluated

during the risk stratification of these patients.